SRS Capital Advisors Inc. Acquires 1,668 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

SRS Capital Advisors Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 620.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,937 shares of the biopharmaceutical company’s stock after buying an additional 1,668 shares during the period. SRS Capital Advisors Inc.’s holdings in Gilead Sciences were worth $179,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC grew its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 293,356 shares of company stock valued at $29,166,240. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 1.1 %

Shares of GILD stock opened at $114.74 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a 50-day moving average price of $98.28 and a two-hundred day moving average price of $90.74. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $117.39. The firm has a market cap of $143.00 billion, a P/E ratio of 310.11, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Analyst Ratings Changes

Several equities research analysts recently commented on GILD shares. Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. BMO Capital Markets increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Wells Fargo & Company increased their price target on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $102.76.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.